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Abstract 
The aim of the work was to understand the toxicity, physically significant descriptors and 
pharmaceutically relevant properties of some imidazoles obtained from the open sources that may 
found to be active against tuberculosis. At present five azoles were modeled for the prediction and 
calculation of descriptors that were carried out by means of computational approach [1]. 
 
Introduction 
 
Current treatment of tuberculosis (TB) is based on drugs that are more than 40 years old. 
Drugs that are active against resistant forms of TB are less potent, more toxic, and need to be taken 
for a long time (18 months). The recent emergence of virtually untreatable extensively drug-resistant 
TB (XDR-TB) poses a new threat to TB control worldwide. Furthermore, effective treatment of TB 
in persons co infected with HIV is complicated due to drug–drug interactions.  
 
Shorter and simpler regimens that are safe, well tolerated, effective against drug-susceptible 
and drug-resistant TB, appropriate for joint HIV–TB treatment, and amenable to routine 
programmatic conditions are needed urgently.  
 
The recent treatment of tuberculosis  
 
WHO recommends the universal use of the 6-month rifampin throughout Short Course 
Chemotherapy (SCC) regimen for the treatment of drug-susceptible TB. For MDR-TB and XDR-
TB are, however, complicated due to long duration, high toxicity, poor tolerance, and high cost, 
resulting in poor outcomes. But found that some of the nitroimidazoles belonging to a novel class of 
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antimicrobacterial agents are active against drug susceptible and drug resistant organism for the 
treatment of MDRTB [2].  
At present a study of ADME (Absorption Distribution Metabolism Elimination) of certain 
azoles was analyzed for predicting the ADME properties prior to expensive experimental 
procedures, such as HTS, can eliminate unnecessary testing on compounds that are doomed to fail, 
it can also focus lead optimization efforts to enhance the desired ADME properties. Finally, 
incorporating ADME predictions as a part of the development process will result in lead 
compounds that are more likely to exhibit satisfactory ADME performances during clinical trials 
 
Nearly 40% of drug candidates fail in clinical trials due to poor ADME properties. These 
late-stage failures contribute significantly to the skyrocketing cost of new drug development. The 
ability to detect problematic candidates early will dramatically reduce the amount of wasted time and 
resources, and streamline the overall development process. 
 
Materials and methods 
 
We used the following molecules for the toxicity prediction. 
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Method 
 
The molecules obtained from the open source was modeled, minimized and were uploaded for the 
descriptor and toxicity prediction and the results were tabulated in the respective tables 1, 2 and 3.  
 
Results and Discussions 
 
The results for the each molecule are tabulated. 
 
Table 1. 
 
Principal descriptors: 
S.No. Descriptors Molecule 1 Molecule2  Molecule 3 Molecule 4 Molecule 5 Range 
1 mol MW 398.389 
 
412.416 
 
428.415 
 
412.416 
 
428.415 
 
103.0/725.0 
2 dipole 11.646 
 
12.18 
 
12.395 
 
11.838 
 
11.447 
 
1.0/12.5 
3 SASA 650.293 
 
683.244 
 
687.03 
 
672.599 
 
686.944 
 
300.0/1000.0 
4 FOSA 51.524 
 
140.243 
 
143.359 
 
124.598 
 
143.892 
 
0.0/750.0 
5 FISA 131.926 
 
131.99 
 
131.761 
 
119.372 
 
131.651 
 
7.0/330.0 
6 PISA 342.267 
 
286.469 
 
287.093 
 
303.779 
 
286.675 
 
0.0/450.0 
7 WPSA 124.576 
 
124.542 
 
124.817 
 
124.85 
 
124.727 
 
0.0/175.0 
8 volume 1117.714 
 
1178.377 
 
1192.293 
 
1166.266 
 
1192.173 
 
500.0/2000.0 
9 PSA 84.097 
 
84.108 
 
92.34 
 
81.341 
 
92.235 
 
7.0 / 200.0 
10 Rotatable bonds 4 
 
4 5 4 5 0.0 /  15.0 
11 donorHB 1 1 1 1 1 0.0 /   6.0 
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 12 accptHB 
 
4.5 
 
4.5 
 
5.25 
 
4.5 
 
5.25 
 
2.0 /  20.0 
13 glob 
 
0.800958 
 
0.789669 
 
0.791489 
 
0.796662 
 
0.791535 
 
0.75 / 0.95 
14 IP(eV) 9.034 
 
9.025 
 
9.006 
 
9.026 
 
9.003 
 
7.9 /  10.5 
15 EA(eV) 
 
1.878* 
 
1.835* 
 
1.873* 
 
1.824* 
 
1.794* 
 
-0.9 / 1.7 
 
 
Table 2. 
 
Predictions for Properties: 
S.No. Descriptors 
 
 
Molecule 1 Molecule 2 Molecule 3 Molecule 4 Molecule 5 Range 
1 QPpolrz 
 
39.277 
 
41.172 
 
41.093 
 
40.853 
 
41.084 
 
13.0/70.0 
2 QPlogPC16 
 
11.795 
 
12.013 
 
12.15 
 
11.918 
 
12.144 
 
4.0 / 18.0 
3 QPlogPoct 
 
19.164 
 
19.767 
 
20.164 
 
19.57 
 
19.899 
 
8.0 /  35.0 
4 QPlogPw 
 
9.568 
 
9.268 
 
9.798 
 
9.275 
 
9.794 
 
4.0 /  45.0 
5 QPlogPo/w 
 
4.366 
 
4.681 
 
4.456 
 
4.715 
 
4.456 
 
-2.0 /  6.5 
6 QPlogS 
 
-6.366 
 
-6.957* 
 
-6.58* 
 
-6.767* 
 
-6.578* 
 
-6.5 / 0.5 
7 CIQPlogS 
 
-6.836 
 
-7.124 
 
-7.149 
 
-7.124 
 
-7.149 
 
-6.5 / 0.5 
8 QPlogKhsa 
 
0.604 
 
0.766 
 
0.609 
 
0.735 
 
0.609 
 
-1.5 / 1.5 
9 QPlogBB 
 
-0.743 
 
-0.783 
 
-0.834 
 
-0.625 
 
-0.833 
 
-3.0 / 1.2 
10 Primary 
metabolites 
2 
 
3 3 3 3 1.0 / 8.0 
11 CNS 
 
-1 -1 -1 0 -1 (-- to ++)      
12 QPlog HERG 
 
-6.385 
 
-6.302 
 
-6.275 
 
-6.271 
 
-6.272 
 
concern 
below 
 -5 
13 QPPCaco 
 
555.71 
 
554.937 
 
557.709 
 
730.963 
 
559.058 
 
<25 poor, 
>500 
14 QPPMDCK 
 
1261.799 
 
1259.362 
 
1270.561 
 
1702.802 
 
1272.43 
 
<25 poor, 
>500 
15 QPlogKp -2.361 -2.559 -2.456 -2.265 -2.456 Kp in cm/hr 
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16 Rule Of Five 
 
0 0 0 0 0 Maximum 
is 4 
17 Rule Of 
Three 
1 1 1 1 1 maximum 
is 3 
18 Percent 
Human Oral 
Absorption 
100 100 100 100 100 100 
 
* indicates the violation of the rules. 
 
Table 3. 
 
Similarity search: 
S.No. Molecules Name 
 
Percentage % 
1 
 
Molecule 1 Timiperone, Benperidol, Quinestradol                               
Talniflumate, Metergoline                                  
86.33, 85.32, 85.22, 84.63, 84.45 
2 Molecule 2 and 
molecule 4 
Talniflumate ,Metergoline, Tioclomarol   
Quinestradol, Estramustine                                  
 
87.58, 86.37, 84.76, 84.71, 84.26 
3 Molecule 3 and 
molecule 5 
Talniflumate, Losartan, Tioclomarol  
Perospirone, Timiperone                                    
 
88.20, 86.42, 85.77, 85.24, 84.30 
 
 
From the above results the azoles have been analyzed in such a way that the molecule 2 to5 
were violating two of the parameter in the principal descriptors and predictions for properties as 
mentioned in the tables.  Also, molecule 1 was violating the parameter solute Electron Affinity in 
principal descriptors. The molecules similar to the known compounds were also tabulated. These 
molecules are showing more drug like properties with less toxicity, for which they can be screened 
against any of the targets in Mycobacterium Tuberculosis in designing the future TB drug.  
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